Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224016 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
A Phase 4 study of Detrusor Hyperreflexia, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 57
- Enrollment target
- 20
- Study locations
NCT00224016: Completed Phase 4 study of Detrusor Hyperreflexia, sponsored by Watson Pharmaceuticals.
NCT00224016 is a Phase 4 study of Detrusor Hyperreflexia that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 57 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00224016, a Phase 4 study of Detrusor Hyperreflexia, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 57 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder.
Primary Outcome
Change from baseline in average volume of urine collected by catheterization
Conditions Studied
Interventions
- DRUG Oxybutynin
Study Locations (20)
New York
- Watson Investigational Site - Albany
- Watson Investigational Site - Buffalo
- Watson Investigational Site - Poughkeepsie
California
- Watson Investigational Site - Orange County
- Watson Investigational Site - San Diego
Missouri
- Watson Investigational Site - Kansas City
- Watson Investigational Site - St Louis
North Carolina
- Watson Investigational Site - Ashville
- Watson Investigational Site - Durham
Arkansas
- Watson Investigational Site - Little Rock
Colorado
- Watson Investigational Site - Denver
District of Columbia
- Watson Investigational Site - Washington D.C.
Michigan
- Watson Investigational Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
What the finished NCT00224016 record still lists
NCT00224016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Detrusor Hyperreflexia appearing as the primary indexed condition, and to 1 intervention - of which Oxybutynin is the first listed.
NCT00224016 names 20 study sites across 15 states, led by New York, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT00224016 about?
NCT00224016 is a clinical study titled "Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition". This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder.
What is the current status of trial NCT00224016?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 57 participants. The study started on 2004-12. Estimated completion is 2008-09.
What conditions does trial NCT00224016 study?
This clinical trial studies the following conditions: Detrusor Hyperreflexia.
What interventions are being tested in trial NCT00224016?
The interventions under investigation include: Oxybutynin (DRUG).
Who is sponsoring clinical trial NCT00224016?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00224016 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Detrusor Hyperreflexia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00224016's enrollment target sits among peer trials
57 1209th of 2000 higher than 788 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia